Related Experiment Video

Updated: Apr 19, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

2.1K

Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label,

Kazunori Toyoda1, Shinichiro Uchiyama, Haruhiko Hoshino

  • 1Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka, 565-8565, Japan.

International Journal of Stroke : Official Journal of the International Stroke Society
|December 10, 2014
PubMed

Insights

Dual antiplatelet therapy (DAPT) with cilostazol may improve secondary ischemic stroke (IS) prevention in high-risk patients. This study compares DAPT involving cilostazol to standard antiplatelet monotherapy for IS recurrence and safety.

Area of Science:

  • Neurology
  • Cardiology
  • Clinical Trials

Background:

  • Monotherapy with antiplatelet agents offers limited efficacy in secondary ischemic stroke (IS) prevention, especially in high-risk individuals.
  • Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel reduces IS recurrence but increases bleeding risk.
  • Cilostazol monotherapy showed efficacy in preventing IS recurrence without increasing bleeding, and DAPT with cilostazol and aspirin did not significantly increase bleeding in patients with intracranial arterial stenosis.

Purpose of the Study:

  • To evaluate the safety and efficacy of DAPT involving cilostazol for secondary IS prevention.
  • To compare DAPT with cilostazol against antiplatelet monotherapy in high-risk IS patients.
  • To assess the potential of cilostazol-based DAPT to improve outcomes in secondary IS prevention.

Main Methods:

  • The Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com) is a multicenter, randomized, open-label trial.
  • 4000 high-risk patients with noncardioembolic IS will be randomized.
  • Treatment arms include aspirin monotherapy, clopidogrel monotherapy, or DAPT with cilostazol and aspirin or clopidogrel for at least one year.

Main Results:

  • The primary outcome is the recurrence of IS.
  • Secondary outcomes include composite events of stroke, all-cause mortality, myocardial infarction, vascular death, and other vascular events.

Conclusions:

  • The CSPS.com trial is expected to determine if DAPT involving cilostazol enhances secondary IS prevention in high-risk populations.
  • Findings will inform clinical practice regarding the use of cilostazol in DAPT regimens for stroke prevention.
Abstract

Keywords:
aspirincerebral infarctioncilostazolclinical trialclopidogreldual antiplatelet therapyischemic strokestroke prevention

More Related Videos

Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System07:35

Author Spotlight: Rehabilitation of Stroke Patients With a Digital Occupational Training System

Published on: December 29, 2023

2.4K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
880
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
7
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
5
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
484
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
437
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
642